Effective Antimicrobial StewaRdship StrategIES (ARIES) (ARIES)
Primary Purpose
Infection, Bacterial
Status
Completed
Phase
Not Applicable
Locations
Singapore
Study Type
Interventional
Intervention
Compulsory CDSS
Sponsored by
About this trial
This is an interventional health services research trial for Infection, Bacterial focused on measuring computerized decision support, prospective review and feedback, antimicrobial stewardship
Eligibility Criteria
Inclusion Criteria:
- Patients who are started on the 1st episode of piperacillin-tazobactam or carbapenem during the study period.
- Medical and surgical wards
Exclusion Criteria:
- Intensive care unit (ICU), high dependency and step-down care wards
Sites / Locations
- Tan Tock Seng Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Voluntary CDSS
Compulsory CDSS
Arm Description
Voluntary use of computerized decision support with prospective review and feedback
Compulsory use of computerized decision support with prospective review and feedback
Outcomes
Primary Outcome Measures
30-day mortality
Death at 30 days
Secondary Outcome Measures
7-day clinical response
resolution of systemic inflammatory response syndrome
30-day re-infection
Re-start of piperacilin-tazobactam or carbapenem 30 days after the cessation of first episode of piperacillin-tazobactam or carbapenem use
30-day readmission
Readmission after the cessation of first episode of piperacillin-tazobactam or carbapenem use
length of stay
Duration of admission
6-months incidence of multi-drug resistant organisms
MRSA, VRE, ESBL, MDR-A. baumannii, XDR- A baumannii, MDR- P. aeruginosa, XDR-P aeruginosa, C difficile , Carbapenem resistant enterobacterales
Diarrhea this admission
Incidence of diarrhea from start of first episode of piperacillin-tazobactam or carbapenem use till discharge
Appropriateness of antibiotics
first episode of piperacillin-tazobactam or carbapenem use according to hospital guidelines. Appropriateness will be described as "yes" or "no".
Index antibiotic days of therapy,
Duration of the first episode of piperacillin-tazobactam or carbapenem use
Gross hospitalization costs
Gross hospitalization costs
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04011657
Brief Title
Effective Antimicrobial StewaRdship StrategIES (ARIES)
Acronym
ARIES
Official Title
Effective Antimicrobial StewaRdship StrategIES (ARIES): Cluster-randomized Trial of a Computerized Decision Support System Versus Antibiotic Prospective Review and Feedback in Antimicrobial Stewardship
Study Type
Interventional
2. Study Status
Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
March 1, 2017 (Actual)
Primary Completion Date
September 30, 2017 (Actual)
Study Completion Date
February 28, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tan Tock Seng Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Background Prospective review and feedback (PRF) of antibiotic prescriptions is a labor-intensive core strategy of antimicrobial stewardship (AMS). The investigators hypothesized that a computerized decision support system (CDSS) providing recommendations for antibiotics, investigations and referrals would reduce the requirement for PRF without causing harm.
Methods A parallel-group, 1:1 block-cluster randomized, cross-over study was conducted in 32 medical and surgical wards from March to August 2017. The intervention arm comprised voluntary use of CDSS at first prescription of piperacillin-tazobactam or a carbapenem, while the control arm was compulsory CDSS. PRF was continued for both arms. Primary outcome was 30-day mortality.
Detailed Description
Increasing antimicrobial resistance due to inappropriate antimicrobial use is a global concern. Multi-disciplinary antimicrobial stewardship teams have become an integral part of the response to this issue. Through prospective review of antibiotic prescriptions and feedback (PRF) to healthcare providers, antimicrobial stewardship has been shown to improve clinical response, reduce adverse effects and mortality. However, this strategy is labor-intensive to implement and skilled healthcare workers are an expensive and scarce resource. Antibiotic computerized decision support systems (CDSS) have been used to facilitate these processes and may circumvent the limitations of lack of manpower. In previous studies, CDSS led to increased susceptibility of Pseudomonas aeruginosa to imipenem and Enterobacteriaceae to gentamicin and ciprofloxacin, and an overall reduction in broad-spectrum antibiotic use. CDSS could improve clinical outcomes. Currently, there are limited studies comparing the combined effects of these two strategies.
At Tan Tock Seng Hospital, a university teaching hospital in Singapore, antimicrobial stewardship has focused on PRF by a multi-disciplinary team since 2009. This team reviews piperacillin-tazobactam and carbapenem orders against hospital antibiotic guidelines from day two of antibiotic prescription. In March 2010, we implemented CDSS triggered at the point of antibiotic ordering and compulsory for the prescriber to review. Prescribers are free to accept or reject the CDSS recommendations. While PRF and CDSS are performed following the same institutional guidelines, there may be differences in physicians' acceptance of recommendations and the accessibility to recommendations between these two interventions. In previous studies, PRF recommendations had an acceptance of 60-70% while compulsory CDSS was 40%. The investigators hypothesized that compulsory CDSS and PRF would improve clinical outcomes compared with voluntary CDSS and PRF, and compulsory CDSS would improve appropriate antibiotic practice and reduce the requirement for subsequent PRF.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection, Bacterial
Keywords
computerized decision support, prospective review and feedback, antimicrobial stewardship
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Masking Description
A parallel-group, 1:1 block-cluster randomized, cross-over study
Allocation
Randomized
Enrollment
1257 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Voluntary CDSS
Arm Type
Experimental
Arm Description
Voluntary use of computerized decision support with prospective review and feedback
Arm Title
Compulsory CDSS
Arm Type
No Intervention
Arm Description
Compulsory use of computerized decision support with prospective review and feedback
Intervention Type
Other
Intervention Name(s)
Compulsory CDSS
Intervention Description
Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
Primary Outcome Measure Information:
Title
30-day mortality
Description
Death at 30 days
Time Frame
Follow-up up to 30 days from the start date of the first episode of piperacillin-tazobactam or carbapenem use
Secondary Outcome Measure Information:
Title
7-day clinical response
Description
resolution of systemic inflammatory response syndrome
Time Frame
Follow-up up to 7 days from the date of the first episode of piperacillin-tazobactam or carbapenem use
Title
30-day re-infection
Description
Re-start of piperacilin-tazobactam or carbapenem 30 days after the cessation of first episode of piperacillin-tazobactam or carbapenem use
Time Frame
Re-start of piperacilin-tazobactam or carbapenem 30 days after the cessation of first episode of piperacillin-tazobactam or carbapenem use
Title
30-day readmission
Description
Readmission after the cessation of first episode of piperacillin-tazobactam or carbapenem use
Time Frame
Readmissions 30 days after the cessation of first episode of piperacillin-tazobactam or carbapenem use
Title
length of stay
Description
Duration of admission
Time Frame
It is assessed from the date of admission till the date of discharge or up to 6 months
Title
6-months incidence of multi-drug resistant organisms
Description
MRSA, VRE, ESBL, MDR-A. baumannii, XDR- A baumannii, MDR- P. aeruginosa, XDR-P aeruginosa, C difficile , Carbapenem resistant enterobacterales
Time Frame
up to 6 months (Clinical cultures only)
Title
Diarrhea this admission
Description
Incidence of diarrhea from start of first episode of piperacillin-tazobactam or carbapenem use till discharge
Time Frame
From the start date from the first episode of piperacillin-tazobactam or carbapenem use until the discharge date or up to 6 months whichever occurred earlier
Title
Appropriateness of antibiotics
Description
first episode of piperacillin-tazobactam or carbapenem use according to hospital guidelines. Appropriateness will be described as "yes" or "no".
Time Frame
It is assessed only once at the point of the first episode of piperacillin-tazobactam or carbapenem use in the index admission. It is only assessed once till discharge or up to 6 months
Title
Index antibiotic days of therapy,
Description
Duration of the first episode of piperacillin-tazobactam or carbapenem use
Time Frame
From the start date of the first episode of piperacillin-tazobactam or carbapenem use to the end date of this antibiotic which is followed up till discharge or up to 6 months.
Title
Gross hospitalization costs
Description
Gross hospitalization costs
Time Frame
Gross hospitalization costs incured from date of admission till date of discharge or up to 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who are started on the 1st episode of piperacillin-tazobactam or carbapenem during the study period.
Medical and surgical wards
Exclusion Criteria:
Intensive care unit (ICU), high dependency and step-down care wards
Facility Information:
Facility Name
Tan Tock Seng Hospital
City
Singapore
ZIP/Postal Code
308433
Country
Singapore
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymized data can be made available only after project agreement is made
Citations:
PubMed Identifier
27080992
Citation
Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016 May 15;62(10):e51-77. doi: 10.1093/cid/ciw118. Epub 2016 Apr 13.
Results Reference
background
PubMed Identifier
28178770
Citation
Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, Gould IM, Ramsay CR, Michie S. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD003543. doi: 10.1002/14651858.CD003543.pub4.
Results Reference
background
PubMed Identifier
25473028
Citation
Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, Ang B, Lye D, Teng CB. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother. 2015 Apr;70(4):1219-25. doi: 10.1093/jac/dku479. Epub 2014 Dec 3.
Results Reference
background
PubMed Identifier
26947617
Citation
Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM, van der Linden PD, Natsch S, Hertogh CMPM, Wolfs TFW, Schouten JA, Kullberg BJ, Prins JM. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016 Jul;16(7):847-856. doi: 10.1016/S1473-3099(16)00065-7. Epub 2016 Mar 3. Erratum In: Lancet Infect Dis. 2016 Jul;16(7):768.
Results Reference
background
PubMed Identifier
20215130
Citation
Yong MK, Buising KL, Cheng AC, Thursky KA. Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. J Antimicrob Chemother. 2010 May;65(5):1062-9. doi: 10.1093/jac/dkq058. Epub 2010 Mar 9.
Results Reference
background
PubMed Identifier
16771625
Citation
Thursky K. Use of computerized decision support systems to improve antibiotic prescribing. Expert Rev Anti Infect Ther. 2006 Jun;4(3):491-507. doi: 10.1586/14787210.4.3.491.
Results Reference
background
PubMed Identifier
23743088
Citation
Leibovici L, Kariv G, Paul M. Long-term survival in patients included in a randomized controlled trial of TREAT, a decision support system for antibiotic treatment. J Antimicrob Chemother. 2013 Nov;68(11):2664-6. doi: 10.1093/jac/dkt222. Epub 2013 Jun 5.
Results Reference
background
PubMed Identifier
26617195
Citation
Chow AL, Lye DC, Arah OA. Mortality Benefits of Antibiotic Computerised Decision Support System: Modifying Effects of Age. Sci Rep. 2015 Nov 30;5:17346. doi: 10.1038/srep17346.
Results Reference
background
Learn more about this trial
Effective Antimicrobial StewaRdship StrategIES (ARIES)
We'll reach out to this number within 24 hrs